- Home
- NMAI vs BBNX Comparison
NMAI vs BBNX Comparison
Compare NMAI & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMAI | BBNX |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.6M | 493.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NMAI | BBNX |
|---|---|---|
| Price | $14.13 | $13.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $23.80 |
| AVG Volume (30 Days) | 85.7K | ★ 1.2M |
| Earning Date | 01-01-0001 | 04-21-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $34.90 |
| Revenue Next Year | N/A | $34.63 |
| P/E Ratio | $21.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.99 | $8.80 |
| 52 Week High | $14.38 | $32.71 |
Technical Indicators
Market Signals| Indicator | NMAI | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 58.26 | 33.33 |
| Support Level | $13.60 | $12.87 |
| Resistance Level | $14.30 | $13.35 |
| Average True Range (ATR) | 0.23 | 1.28 |
| MACD | 0.01 | -0.56 |
| Stochastic Oscillator | 82.64 | 8.87 |
Price Performance
Historical ComparisonAbout NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.